BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 314 filers reported holding BLUEBIRD BIO INC in Q2 2018. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $5,279,000 | -18.6% | 41,505 | +0.7% | 0.01% | -23.5% |
| Q1 2019 | $6,482,000 | +58.6% | 41,200 | 0.0% | 0.02% | +41.7% |
| Q4 2018 | $4,087,000 | -22.4% | 41,200 | +14.2% | 0.01% | -7.7% |
| Q3 2018 | $5,267,000 | -1.2% | 36,075 | +6.2% | 0.01% | -7.1% |
| Q2 2018 | $5,331,000 | -8.9% | 33,964 | -0.9% | 0.01% | -12.5% |
| Q1 2018 | $5,855,000 | +20.7% | 34,288 | +25.9% | 0.02% | +23.1% |
| Q4 2017 | $4,851,000 | +18.5% | 27,236 | -8.6% | 0.01% | +8.3% |
| Q3 2017 | $4,094,000 | +34.1% | 29,810 | +2.5% | 0.01% | +33.3% |
| Q2 2017 | $3,054,000 | +20.9% | 29,075 | +4.6% | 0.01% | +12.5% |
| Q1 2017 | $2,526,000 | +20.5% | 27,785 | -18.3% | 0.01% | +14.3% |
| Q4 2016 | $2,097,000 | -6.6% | 33,990 | +2.6% | 0.01% | -12.5% |
| Q3 2016 | $2,246,000 | +56.2% | 33,140 | -0.2% | 0.01% | +60.0% |
| Q2 2016 | $1,438,000 | +0.9% | 33,220 | -0.9% | 0.01% | 0.0% |
| Q1 2016 | $1,425,000 | – | 33,530 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
| qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
| Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
| Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
| Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
| HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
| Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
| PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
| Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
| Summit X, LLC | 103,424 | $651,000 | 0.19% |